Tag: StreetInsider.com
-
Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11 – StreetInsider.com
Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11StreetInsider.com“The prevalence of childhood asthma in the U.S. is high, at more than six million patients, and that number continues to rise,” said Dr. Erwin Gelfand, Chairman, Department of Pediatrics at National Jewish Health. “For this young population of…
-
UPDATE: Glaxo’s (GSK) Severe Asthma Drug Mepolizumab Found Effective in … – StreetInsider.com
UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in …StreetInsider.comGlaxoSmithKline (NYSE: GSK) severe asthma drug, mepolizumab, is effective in adults, FDA panel says, according to Bloomberg. UPDATE – Last November, Glaxo announced that it filed regulatory submissions in the USA and Europe for mepolizumab for … View full post on asthma – Google News
-
AstraZeneca (AZN), Abbott (ABT) to Develop Diagnostic Tests for Asthma Patients – StreetInsider.com
AstraZeneca (AZN), Abbott (ABT) to Develop Diagnostic Tests for Asthma PatientsStreetInsider.comAstraZeneca (NYSE: AZN) announced that it has entered an agreement with Abbott (NYSE: ABT), a global healthcare company, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the …AstraZeneca Enters Companion Diagnostic Test Deal With AbbottLondon South…
-
GlaxoSmithKline (GSK), Theravance (THRX) Announces US FDA Approval of … – StreetInsider.com
GlaxoSmithKline (GSK), Theravance (THRX) Announces US FDA Approval of …StreetInsider.comGlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) announced that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 …Glaxo Wins U.S. Approval to Sell Breo Only to Adults With AsthmaBloombergFDA approves…
-
Dupilumab Could End of Being ‘Blockbuster’ Asthma Drug – Analyst (SNY) (REGN) – StreetInsider.com (subscription)
Dupilumab Could End of Being 'Blockbuster' Asthma Drug – Analyst (SNY) (REGN)StreetInsider.com (subscription)Dupilumab may debut in 2018 as a treatment for skin and/or asthma conditions, Fernandez said. He observes the large market for asthma, with competition expected from the likes of AstraZenece (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), and others. View full post on asthma –…